Erysipelothrix rhusiopathiae

Erysipelothrix rhusiopathiae is a Gram-positive, catalase-negative, rod-shaped, non-spore-forming, nonmotile bacterium that primarily acts as a pathogen in animals, causing erysipelas (diamond skin disease in pigs) in species like pigs, turkeys, and hens, with zoonotic potential leading to erysipeloid—a localized skin infection—in humans via cutaneous exposure during occupational handling of infected animal products.[1][3][7] It survives in soil, water, and feces for weeks to months, facilitating environmental transmission, and expresses virulence factors such as neuraminidase for host cell invasion and a heat-labile capsule.[1] In humans, infections rarely progress to sepsis or endocarditis, particularly in those with predisposing conditions.[1][9] Treatment relies on antibiotics like penicillin and cephalosporins, though recent isolates show high resistance to amoxicillin and variable susceptibility to others, complicating therapy in veterinary and human cases.[1][2][6] Vaccines are used in pigs, poultry, and sheep to mitigate economic losses, but no specific human vaccines exist.[4] This organism belongs to the class Erysipelotrichia in the phylum Firmicutes and is not a molecular therapeutic target like receptors or enzymes but a microbial pathogen managed through antimicrobial and preventive strategies.[8][12]

Other names

E. rhusiopathiae

Beta-lactam antibiotics (penicillins, cephalosporins, carbapenems like imipenem) inhibit cell wall synthesis; tetracyclines inhibit protein synthesis; quinolones inhibit DNA gyrase; macrolides (erythromycin) and lincosamides (clindamycin) inhibit protein synthesis